# Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer

> **NCT05740501** · — · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 13 (actual)

## Conditions studied

- Lung Non-Small Cell Carcinoma
- Melanoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Electronic Health Record Review
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT05740501
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-26
- **Primary completion:** 2020-01-03
- **Final completion:** 2020-01-03
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05740501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05740501, "Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05740501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*